drugset / Trial / NCT00280566

Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)

NCT00280566

Phase 3 Completed 584 enrolled Viatris Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine if ziprasidone plus a mood stabilizer will continue to be a safe and effective treatment regimen for adults with Bipolar I Disorder (manic or mixed symptoms) after they have achieved 8 consecutive weeks of symptom improvement on the regimen.

Timeline

Start
2005-12
Primary completion
2008-05
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Ziprasidone Small molecule 40 mg Oral
Subject Ziprasidone Small molecule 60 mg Oral
Subject Ziprasidone Small molecule 80 mg Oral